1	Ramon Rossi Lopez - <u>rlopez@lopezmchugh.com</u> (California Bar Number 86361; admitted <i>pro hac vice</i>)		
2	Lopez McHugh LLP		
3	100 Bayview Circle, Suite 5600 Newport Beach, California 92660 949-812-5771		
4			
5	Mark Stephen O'Connor (011029) – <u>mark.oconnor@gknet.com</u> Gallagher & Kennedy, P.A. 2575 East Camelback Road		
6	Phoenix, Arizona 85016-9225 602-530-8000		
7 8	Counsel for Plaintiffs		
9	UNITED STATES DISTRICT COURT		
10	DISTRICT OF ARIZONA		
11	In Re Bard IVC Filters Products Liability Litigation	No. MD-15-02641-PHX-DGC	
12	SHERR-UNA BOOKER, an individual,	PLAINTIFF'S NOTICE OF FILING PUBLIC EXHIBITS TO PLAINTIFFS'	
13	Plaintiff,	OMNIBUS SEPARATE STATEMENT OF FACTS IN SUPPORT OF THEIR	
14 15	v.	RESPONSE TO DEFENDANTS' MOTION FOR SUMMARY JUDGMENT	
16 17	C.R. BARD, INC., a New Jersey corporation and BARD PERIPHERAL VASCULAR, an Arizona corporation,		
18	Defendants.		
19	Plaintiff hereby files, attached to this	s Notice, the public/non-confidential exhibits in	
20	·	atement of Facts in Support of Their Response	
21	to Defendants' Motion For Summary Judgr	••	
22	DATED this 23 rd day of October, 20		
23	G	ALLAGHER & KENNEDY, P.A.	
24		,	
25	В	y:/s/ Mark S. O'Connor	
26		Mark S. O'Connor 2575 East Camelback Road	
27		Phoenix, Arizona 85016-9225	
28	L	OPEZ McHUGH LLP Ramon Rossi Lopez (CA Bar No. 86361)	

(admitted *pro hac vice*) 100 Bayview Circle, Suite 5600 Newport Beach, California 92660 Counsel for Plaintiffs **CERTIFICATE OF SERVICE** I hereby certify that on this 23rd day of October 2017, I electronically transmitted the attached document to the Clerk's Office using the CM/ECF System for filing and transmittal of a Notice of Electronic Filing. /s/ Gay Mennuti

INDEX OF EXHIBITS

- I		INDEX OF EXHIBITS
	Para No.	
2	Ex. No.	Description
3	1	US FDA Clinical Data Summary of the Simon Nitinol Filter, attached as Exhibit 1, BPVE-01-00280772
4	2	Deposition of John McDermott, dated Feb. 5, 2014 at
5		83:9-92:18; 142:18-144:1; 152:16-154:4; 166:9-168:18; 190:11-195:13; 196:12-197:16; 228:17-229:8; 288:13-289:7; 290:15-290:25; 306:14 – 308:11; 349:17-21
6 7	3	Product Performance Specification Recovery Filter and Femoral Delivery System, dated Nov. 2003, BPVE-01-00010390
8	4	Email from D. Ciavarella to Barry & Ganser re G2 Caudal Migrations, dated Dec. 27, 2005, BPVE-01-00028224
9 10	6	Deposition of Donna B. Tillman, dated June 12, 2014 at 101:20-23, 115:23-116:3, 119:23-120:7; 193:6-194:20
11	11	Deposition of Murray R. Asch, dated May 2, 2016 at12:14-24; 23:7-24:19; 26:8-15; 195:14-24; 40:19-41:11
12 13	12	Murray R. Asch, MD, FRCPC, <i>Initial Experience in Humans with a New Retrievable IVC Filter</i> , Radiology 2002; 225:835-844 ("Asch Study Article")
14	20	Deposition of Robert Carr, dated Dec. 19, 2014 at 120:20–122:1
15 16	22	Deposition of Andrzej Chanduszko, dated Oct. 10, 2013 at 51:23–52:7
17	23	Recovery Filter System for use in the Vena Cava, Information for Use, BPVE-01-00435559
18 19	27	Special Design Review for Recovery (Project #s 7081 and 8008) – Meeting Minutes, dated Dec. 9, 2003, BPVE-01-00407525
20	28	Email exchange between Janet Hudnall to David Rausch dated Feb. 26-27, 2004, BPVE-01-00373887
21 22	30	Email from Alex Tessmer to Robert Carr dated Feb. 25, 2004, BPVE-01-00410985
23	31	Characterization of Recovery Filter Migration Resistance in Comparison to Competitive Product Phase 1, BPVE-01-00276094
24	32	Email from Alex Tessmer to Charlie Benware and others Mar. 24, 2004, BPVE-01-
25	52	00330122
26	33	Engineering Test Report No. ETR-04-03-02, BPV-17-01-00001198-208
27	35	Health Hazard Evaluation, dated Dec. 17, 2004, BPVE-01-01019821
28		

1	37	Deposition of Chad Modra, dated Mar. 28, 2013 at 181:1-19; 183:9-12
2	38	Crisis Communication Plan, BPV-17-01-00165419
3		
4	39	Email from John Lehman, dated April 15, 2004, BPV-17-01-00165419
5	40	Email from Jason Greer to Janet Hudnall, dated Mar. 16, 2006, BPVE-01-00946624
6	41	Remedial Action Plan dated April 21, 2004, BPV-17-01-00153578
7 8 9	42	April 13, 2004, May 8, 2004; May 30, 2004; July 24, 2004; August 16, 2004; November 15, 2004; November 28, 2004) Recovery Filter Detached Limbs—Patient Comparison Matrix dated November 1, 2005, BPV-17-01-00035618
10	43	HHE, July 9, 2004, BPV17-01-00002145
11	46	Updated Health Hazard Evaluation, June 30, 2004, BPVEFILTER-01000014836
12	47	Bard Recovery FAQ dated July 15, 2004, BPVE-01-00268921-923
13	49	Internal Q&A dated Aug. 30, 2004, BPVE-01-00033810
1415	50	2004 Recovery Marketing Brochure, BPV-17-01-00007760-763
16	51	Deposition of Jack Sullivan (Vol. I), dated Sept. 16, 2016 at 54:10-55:6, 56:2-57:2, 59:15-61:4; 80:16-81:12
17	54	Email from Chris Ganser to T. Ring dated April 19, 2005, BPVE-01-00434275
18 19	55	Email from Jason Greer to Nicole Alpie and others dated July 16, 2005, BPV-DEP-00005665-666
20	56	Executive Summary dated August 3, 2005, BPV-17-01-00170083-084
21	57	Janet Hudnall, Avijit Mukherjee, and Robert Carr email chain, August 25-26, 2004, BPVE-01-00008821
22		
23	59	Email from Janet Hudnall to John McDermott, Feb. 11, 2005, BPVE-01-00167251
24	66	Marketing Brochure for Recovery G2 Filter System, BPV-17-01-00137588
2526	68	Deposition of Christine Brauer, dated May 23, 2014 216:1-217:20; 224:6-225:15
27	73	Email chain between Chris Ganser, Gin Schultz, Cindi Walcott, and others, November 7-14, 2005, BPVE-01-01510714
28		

Case 2:15-md-02641-DGC Document 8375 Filed 10/23/17 Page 5 of 6

1	74	Bard internal spreadsheet of Filter Sales and MAUDE data through November 7, 2005/Q3 2005, BPVE-01-01510717
2 3	76	Email chain between David Ciaverella, Cindi Walcott, and others, December 20-27, 2015, BPVE-01-00028224
4	82	Memo from Brian Barry to John Weiland re Competitive Filter Data, May 2, 2005, BPV-01-00098737
5		01-000/6/3/
6	83	Bard IVC filter model sales and complications comparison spreadsheet, BPVEFILTER-01-00050487
7 8	85	Binkert, et al., Technical Success and Safety of Retrieval of the G2 Filter in a Prospective, Multicenter Study, J. Vasc. Interv. Radiol. 2009
9	88	Bard Peripheral Vascular Filter Franchise Review, May 6, 2008, BPVE-01-00622862-900
10	91	Deposition of Patrick McDonald, dated July 29, 2016 at 103:23-104:1
11	92	Email chain between Brian Hudson, Kevin Bovee, and Chad Modra, June 28, 2011,
12		BPVEFILTER-01-00037661-62
13 14	93	F.C. Lynch & S. Kekulawela, Removal of the G2 Filter: Differences between Implantation Times Greater than and Less than 180 Days, 20 J. Vasc. Interv. Radiol. 1200 (2009)
15 16	94	W. Nicholson et al., Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade, 170 Arch. Intern. Med. 1827 (2010)
17 18	97	Deposition of Christopher Smith, dated Aug. 3, 2017 at 126:6-18, 130:6-20; 141:18-24, 144:16-20; 155:6-156:4; 156:5-156:25, 158:1-159:5; 184:9-21
19	103	Deposition of Abithal Raji-Kubba, dated July 18, 2016 at 167:11-168:8
20	110	Deposition of Clement Grassi, M.D., dated July 30, 2014 at126:6-18, 130:6-20; 69:23-
21		70:10; 232:14-19; 238:2-239:2; 239:3-17; 325:15-326:6
22	111	G3 Vena Cava Filter Design Input Summary Report, BPVE-01-0061776
23 24	113	Deposition of David Ciavarella, dated Nov. 12, 2013 at 220:16-221:15
25	116	Deposition of Tim Fischer, March 29, 2017 at 7:16-24; 281:13-283:1; 282:4-283:3
26	117	Deposition of Mark Moritz, M.D., dated July 18, 2017 at 85:12-86:3
27		

Bard Peripheral Vascular's Supplemental Responses to Plaintiffs Doris and Alfred Jones's First Set of Requests for Admissions to Bard Peripheral Vascular, Inc.
Eclipse Vena Cava Filter, Femoral Vein Approach, Instructions for Use
G2X Vena Cava Filter, Femoral Vein Approach, Instructions for Use
G2 Filter System, Femoral Vein Approach, Instructions for Use
BPVEFILTER-01-00002447
Deposition of Thomas Kinney, M.D., dated June 17, 2017
Deposition of Anne Roberts, M.D., dated July 7, 2017